| |
|
|
|
Adamas Pharma  
|
|
2.75 0.06 (0.02%) |
06-02 16:00 |
|
Open: |
2.71 |
Pre close: |
2.69 |
Target:
|
3.60 
|
|
High: |
2.81 |
Low: |
2.65 |
Resistance:
|
3.08
3.48
|
|
Volume: |
213,121 |
Market Cap: |
77M |
Support:
|
2.43
2.02
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
2.76
|
MACD |
MACD(12,26):
|
-0.11  |
|
MA(20): |
2.87 |
Signal(12,26,9): |
-0.11 |
|
MA(100): |
3.86 |
Stochastic Oscillator |
%K(14,3):
|
36.25 |
|
MA(250): |
4.79 |
%D(3): |
34.56 |
|
Average Volume(K) |
3-Month: |
33615
|
52-Week |
High:
|
7.78 |
|
10-Days: |
33848 |
Low: |
1.90 |
|
RSI |
RSI(14):
|
43.42 |
Change(%): |
-42.7 |
|
Financials, Statistics and Valuation |
|
EPS |
-3.313 |
Return on Equity (ttm) |
-383.6 |
Shares Out. (M) |
28.16 |
|
EPS Est. Current Year |
-3.770 |
Return on Assets (ttm) |
-26.1 |
Shares Float (M) |
20.33 |
|
EPS Est. Next Year |
-3.420 |
PEG Ratio |
0.00 |
% Held by Insiders |
2.81 |
|
EPS Est. Next Quarter |
-1.170 |
Qtrly Rev. Growth |
24.1 |
% Held by Institutions |
79.07 |
|
Forward EPS |
-3.800 |
Gross Profit (p.s.) |
1.853 |
Shares Short (K) |
1020 |
|
Book Value (p.s.) |
-0.560 |
EBITDA (p.s.) |
-2.689 |
P/E |
-0.83 |
|
Sales Per Share |
2.040 |
Qtrly Earnings Growth |
0.00 |
P/BV |
-4.91 |
|
Profit Margin |
-160.44 |
Operating Cash Flow
(M) |
-77.17 |
P/S |
1.35 |
|
Operating Margin |
-133.66 |
Levered Free Cash Flow
(M) |
-50.97 |
P/CF |
-1.00 |
|
|
|
|
|
|
